A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus
Primary Purpose
Diabetes Mellitus, Type 2
Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
Placebo
PF-06882961
Sponsored by

About this trial
This is an interventional treatment trial for Diabetes Mellitus, Type 2
Eligibility Criteria
Inclusion Criteria:
- Patients with T2DM who are treated with metformin and/or diet and exercise
- HbA1c greater than or equal to 7% and less than or equal to 10.5%
- Total body weight >50 kg (110 lb) with BMI 24.5 to 45.4 kg/m^2
Exclusion Criteria:
- Any condition possibly affecting drug absorption
- Diagnosis of Type 1 diabetes
- History of myocardial infarction, unstable angina, arterial revascularization, stroke, heart failure, or transient ischemic attack within 6 months of screening
- Any malignancy not considered cured
- Personal or family history of MTC or MEN2, or participants with suspected MTC
- Acute pancreatitis or history of chronic pancreatitis
- Symptomatic gallbladder disease
- Known medical history of active proliferative retinopathy and/or macular edema
- Known medical history of active liver disease, including chronic active hepatitis B or C, or primary biliary cirrhosis
- Known history of HIV
- Supine blood pressure greater than or equal to 160 mmHg (systolic) or greater than or equal to 100 mmHg (diastolic)
- Clinically relevant ECG abnormalities
- Positive urine drug test
Sites / Locations
- Holy Trinity Medical Clinic
- Innovative Clinical Research, Inc.
- Long Beach Clinical Trials Services, Inc.
- National Research Institute
- Catalina Research Institute, LLC
- Empire Clinical Research
- Rancho Cucamonga Clinical Research
- Encompass Clinical Research
- University Clinical Investigators, Incorporated
- San Fernando Valley Health Institute, LLC
- Diablo Clinical Research Incorporated
- Accel Research Sites - DeLand Clinical Research Unit
- East Coast Institute for Research, LLC
- East Coast Institute for Research, LLC
- NewPhase Clinical Trials, Corp.
- New Horizon Research Center
- Sunshine Research Center, Inc
- Andres Patron D.O. P.A.
- Ellipsis Group
- East Coast Institute for Research, LLC
- Cedar Crosse Research Center
- Buynak Clinical Research
- Viable Research Management LLC
- Premier Research
- PharmQuest
- Lillestol Research LLC
- Velocity Clinical Research
- Conrad Clinical Research
- Family Medical Associates
- Preferred Primary Care Physicians, Inc.
- Spartanburg Medical Research
- Palmetto Clinical Research
- Palmetto Primary Care Physicians (physicals only)
- Dallas Diabetes Research Center
- Endocrine Associates
- PrimeCare Medical Group
- Juno Research, LLC
- Northeast Clinical Research of San Antonio
- Sun Research Institute
- DM Clinical Research
- Martin Diagnostic Clinic
- Rainier Clinical Research Center, Inc.
- MHAT Dobrich AD
- Medical Center ASKLEPII OOD
- UMHAT Pulmed
- Fourth MHAT - Sofia EAD
- MHAT "Doverie" AD
- MC "New rehabilitation center" EOOD
- GA Research Associates Ltd.
- Aggarwal and Associates Limited
- Manna Research (Toronto)
- Manna Research (Quebec)
- Manna Research (Mirabel)
- Diex Recherche Sherbrooke Inc.
- Diex Recherche Victoriaville Inc.
- Diex Recherche Quebec Inc.
- Centre de Recherche Saint-Louis
- Alpha Recherche Clinique
- Belinus Orvosi es Szamitastechnikai Bt
- Debreceni Egyetem Klinikai Kozpont
- CRU Hungary Kft.
- Borbanya Praxis Egeszsegugyi KFT
- Clinfan Kft.
- Yonsei University-Wonju Severance Christian Hospital
- Hanyang University Guri Hospital
- Ajou University Hospital
- Samsung Medical Center
- Zdrowie Osteo-Medic s.c. Lidia i Artur Racewicz, Agnieszka i Jerzy Supronik
- Medyczne Centrum Diabetologiczno-Endokrynologiczno-Metaboliczne DIAB-ENDO-MET Sp. z o. o.
- Prywatny Gabinet Lekarski i Wizyty Lekarskie Jan Ruxer
- MEDICOME Sp. z o.o.
- KO-MED CENTRA KLINICZNE Sp. z o.o. Ośrodek Badań Klinicznych w Puławach
- Centralny Szpital Kliniczny MSWiA
- Metabol KLINIK s.r.o.
- Medispektrum, s.r.o
- HUMAN-CARE, s.r.o.
- SchronerMED s.r.o.
- Funkystuff, s.r.o.
- DIAB s.r.o.
- MUDr. Jana Rociakova, s.r.o.
- Far Eastern Memorial Hospital
- Taichung Veterans General Hospital
- National Cheng Kung University Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Arm Type
Placebo Comparator
Experimental
Experimental
Experimental
Experimental
Experimental
Arm Label
Placebo
PF-06882961 2.5 milligrams (mg)
PF-06882961 10 mg
PF-06882961 40 mg
PF-06882961 80 mg
PF-06882961 120 mg
Arm Description
Participants will be titrated up to 2 weeks to reach desired dose level
Participants will be titrated up to 4 weeks to reach desired dose level
Participants will be titrated up to 6 weeks to reach desired dose level
Outcomes
Primary Outcome Measures
Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 16
HbA1c can be used as a diagnostic test for diabetes. The target HbA1c level for people with diabetes is usually less than 7%.
Secondary Outcome Measures
Percentage of Participants Achieving Less Than (<) 7% Glycated Hemoglobin (HbA1c) Levels
HbA1c can be used as a diagnostic test for diabetes. The target HbA1c level for people with diabetes is usually less than 7%.
Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 2
HbA1c can be used as a diagnostic test for diabetes. The target HbA1c level for people with diabetes is usually less than 7%.
Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 4
HbA1c can be used as a diagnostic test for diabetes. The target HbA1c level for people with diabetes is usually less than 7%.
Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 6
HbA1c can be used as a diagnostic test for diabetes. The target HbA1c level for people with diabetes is usually less than 7%.
Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 8
HbA1c can be used as a diagnostic test for diabetes. The target HbA1c level for people with diabetes is usually less than 7%.
Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 12
HbA1c can be used as a diagnostic test for diabetes. The target HbA1c level for people with diabetes is usually less than 7%.
Change From Baseline in Fasting Plasma Glucose at Week 2
The fasting plasma glucose test measures the levels of glucose (sugar) in the blood, with a normal range of 70 milligram per deciliter (mg/dL) to 99 mg/dL.
Change From Baseline in Fasting Plasma Glucose at Week 4
The fasting plasma glucose test measures the levels of glucose (sugar) in the blood, with a normal range of 70 mg/dL to 99 mg/dL.
Change From Baseline in Fasting Plasma Glucose at Week 6
The fasting plasma glucose test measures the levels of glucose (sugar) in the blood, with a normal range of 70 mg/dL to 99 mg/dL.
Change From Baseline in Fasting Plasma Glucose at Week 8
The fasting plasma glucose test measures the levels of glucose (sugar) in the blood, with a normal range of 70 mg/dL to 99 mg/dL.
Change From Baseline in Fasting Plasma Glucose at Week 12
The fasting plasma glucose test measures the levels of glucose (sugar) in the blood, with a normal range of 70 mg/dL to 99 mg/dL.
Change From Baseline in Fasting Plasma Glucose at Week 16
The fasting plasma glucose test measures the levels of glucose (sugar) in the blood, with a normal range of 70 mg/dL to 99 mg/dL.
Change From Baseline in Body Weight at Week 2
Weight was recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg.
Change From Baseline in Body Weight at Week 4
Weight was recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg.
Change From Baseline in Body Weight at Week 6
Weight was recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg.
Change From Baseline in Body Weight at Week 8
Weight was recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg.
Change From Baseline in Body Weight at Week 12
Weight was recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg.
Change From Baseline in Body Weight at Week 16
Weight was recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg.
Number of Participants With Treatment Emergent Adverse Events (Adverse Events [AEs] and Serious Adverse Events [SAEs])
An adverse event (AE) was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. A serious AE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening; initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect. Any such events with initial onset or increasing in severity after the first dose of study treatment were counted as treatment-emergent.
Number of Participants With Treatment Emergent Clinical Laboratory Abnormalities Without Regard to Baseline Abnormality
Following laboratory parameters were assessed against pre-defined abnormality criteria: hematology (hemoglobin, hematocrit, erythrocytes, reticulocytes, platelets, leukocytes, lymphocytes, neutrophils, basophils, eosinophils, monocytes, activated partial thromboplastin time, prothrombin time, PT/INR, reticulocytes); chemistry (indirect bilirubin, direct bilirubin, protein, albumin, blood urea nitrogen, creatinine, creatine kinase, urate, calcium, sodium, potassium, chloride, bicarbonate, urine urobilinogen); urinalysis (pH, urine glucose, urine ketones, urine protein, urine hemoglobin, nitrites, leukocyte esterase, urine erythrocytes, urine leukocytes, urine hyaline casts, urine bilirubin); lipid panel (low density lipoprotein cholesterol, high density lipoprotein cholesterol).
Number of Participants With Treatment Emergent Vital Signs Abnormalities
Vital signs abnormality criteria: 1) supine systolic blood pressure (SBP) <90 millimeters of mercury (mmHg); 2) supine diastolic blood pressure (DBP) <50 mmHg; 3) supine pulse rate <40 or >120 beats per minute (bpm); 4) change from baseline (increase or decrease) in supine SBP greater than or equal to (>=) 30 mmHg; 5) change from baseline (increase or decrease) in supine DBP >= 20 mmHg.
Number of Participants With Treatment Emergent ECG Abnormalities
ECG categorical abnormality criteria: 1. PR interval (the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization): a) greater than or equal to (>=) 300 millisecond (msec), b) >=25% increase when baseline is > 200 msec or >=50% increase when baseline is less than or equal to (<=) 200 msec.
2. QRS interval (time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization): a) >=140 msec, b) >=50% increase from baseline.
3. QTcF interval (QT corrected using the Fridericia formula): a) >450 msec and <=480 msec, b) >480 msec and <=500 msec, c) >500 msec, d) >30 msec and <=60 msec increase from baseline, e) >60 msec increase from baseline.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03985293
Brief Title
A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus
Official Title
A 16-WEEK, PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE DAILY PF-06882961 ADMINISTRATION IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED ON METFORMIN OR DIET AND EXERCISE
Study Type
Interventional
2. Study Status
Record Verification Date
June 2022
Overall Recruitment Status
Completed
Study Start Date
October 15, 2019 (Actual)
Primary Completion Date
June 8, 2021 (Actual)
Study Completion Date
July 7, 2021 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Pfizer
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This multicenter, randomized, double-blind, placebo controlled, parallel group study is being conducted to provide data on efficacy, safety, tolerability and pharmacokinetics (PK) of multiple dose levels of PF-06882961 in adults with type 2 diabetes mellitus (T2DM) inadequately controlled on metformin and/or diet and exercise. In addition, the study is intended to enable selection of efficacious doses for future clinical development of PF-06882961.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
412 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Title
PF-06882961 2.5 milligrams (mg)
Arm Type
Experimental
Arm Title
PF-06882961 10 mg
Arm Type
Experimental
Arm Title
PF-06882961 40 mg
Arm Type
Experimental
Arm Description
Participants will be titrated up to 2 weeks to reach desired dose level
Arm Title
PF-06882961 80 mg
Arm Type
Experimental
Arm Description
Participants will be titrated up to 4 weeks to reach desired dose level
Arm Title
PF-06882961 120 mg
Arm Type
Experimental
Arm Description
Participants will be titrated up to 6 weeks to reach desired dose level
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
4 matching placebo tablets taken twice a day (BID)
Intervention Type
Drug
Intervention Name(s)
PF-06882961
Intervention Description
Participants will be randomized to one of 5 active doses (2.5, 10, 40, 80, or 120 mg), taking 4 tablets twice daily for 16 weeks.
Primary Outcome Measure Information:
Title
Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 16
Description
HbA1c can be used as a diagnostic test for diabetes. The target HbA1c level for people with diabetes is usually less than 7%.
Time Frame
Baseline, Week 16
Secondary Outcome Measure Information:
Title
Percentage of Participants Achieving Less Than (<) 7% Glycated Hemoglobin (HbA1c) Levels
Description
HbA1c can be used as a diagnostic test for diabetes. The target HbA1c level for people with diabetes is usually less than 7%.
Time Frame
Baseline, Week 16
Title
Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 2
Description
HbA1c can be used as a diagnostic test for diabetes. The target HbA1c level for people with diabetes is usually less than 7%.
Time Frame
Baseline, Week 2
Title
Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 4
Description
HbA1c can be used as a diagnostic test for diabetes. The target HbA1c level for people with diabetes is usually less than 7%.
Time Frame
Baseline, Week 4
Title
Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 6
Description
HbA1c can be used as a diagnostic test for diabetes. The target HbA1c level for people with diabetes is usually less than 7%.
Time Frame
Baseline, Week 6
Title
Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 8
Description
HbA1c can be used as a diagnostic test for diabetes. The target HbA1c level for people with diabetes is usually less than 7%.
Time Frame
Baseline, Week 8
Title
Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 12
Description
HbA1c can be used as a diagnostic test for diabetes. The target HbA1c level for people with diabetes is usually less than 7%.
Time Frame
Baseline, Week 12
Title
Change From Baseline in Fasting Plasma Glucose at Week 2
Description
The fasting plasma glucose test measures the levels of glucose (sugar) in the blood, with a normal range of 70 milligram per deciliter (mg/dL) to 99 mg/dL.
Time Frame
Baseline, Week 2
Title
Change From Baseline in Fasting Plasma Glucose at Week 4
Description
The fasting plasma glucose test measures the levels of glucose (sugar) in the blood, with a normal range of 70 mg/dL to 99 mg/dL.
Time Frame
Baseline, Week 4
Title
Change From Baseline in Fasting Plasma Glucose at Week 6
Description
The fasting plasma glucose test measures the levels of glucose (sugar) in the blood, with a normal range of 70 mg/dL to 99 mg/dL.
Time Frame
Baseline, Week 6
Title
Change From Baseline in Fasting Plasma Glucose at Week 8
Description
The fasting plasma glucose test measures the levels of glucose (sugar) in the blood, with a normal range of 70 mg/dL to 99 mg/dL.
Time Frame
Baseline, Week 8
Title
Change From Baseline in Fasting Plasma Glucose at Week 12
Description
The fasting plasma glucose test measures the levels of glucose (sugar) in the blood, with a normal range of 70 mg/dL to 99 mg/dL.
Time Frame
Baseline, Week 12
Title
Change From Baseline in Fasting Plasma Glucose at Week 16
Description
The fasting plasma glucose test measures the levels of glucose (sugar) in the blood, with a normal range of 70 mg/dL to 99 mg/dL.
Time Frame
Baseline, Week 16
Title
Change From Baseline in Body Weight at Week 2
Description
Weight was recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg.
Time Frame
Baseline, Week 2
Title
Change From Baseline in Body Weight at Week 4
Description
Weight was recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg.
Time Frame
Baseline, Week 4
Title
Change From Baseline in Body Weight at Week 6
Description
Weight was recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg.
Time Frame
Baseline, Week 6
Title
Change From Baseline in Body Weight at Week 8
Description
Weight was recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg.
Time Frame
Baseline, Week 8
Title
Change From Baseline in Body Weight at Week 12
Description
Weight was recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg.
Time Frame
Baseline, Week 12
Title
Change From Baseline in Body Weight at Week 16
Description
Weight was recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg.
Time Frame
Baseline, Week 16
Title
Number of Participants With Treatment Emergent Adverse Events (Adverse Events [AEs] and Serious Adverse Events [SAEs])
Description
An adverse event (AE) was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. A serious AE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening; initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect. Any such events with initial onset or increasing in severity after the first dose of study treatment were counted as treatment-emergent.
Time Frame
Baseline up to Week 21
Title
Number of Participants With Treatment Emergent Clinical Laboratory Abnormalities Without Regard to Baseline Abnormality
Description
Following laboratory parameters were assessed against pre-defined abnormality criteria: hematology (hemoglobin, hematocrit, erythrocytes, reticulocytes, platelets, leukocytes, lymphocytes, neutrophils, basophils, eosinophils, monocytes, activated partial thromboplastin time, prothrombin time, PT/INR, reticulocytes); chemistry (indirect bilirubin, direct bilirubin, protein, albumin, blood urea nitrogen, creatinine, creatine kinase, urate, calcium, sodium, potassium, chloride, bicarbonate, urine urobilinogen); urinalysis (pH, urine glucose, urine ketones, urine protein, urine hemoglobin, nitrites, leukocyte esterase, urine erythrocytes, urine leukocytes, urine hyaline casts, urine bilirubin); lipid panel (low density lipoprotein cholesterol, high density lipoprotein cholesterol).
Time Frame
Baseline Through Week 21
Title
Number of Participants With Treatment Emergent Vital Signs Abnormalities
Description
Vital signs abnormality criteria: 1) supine systolic blood pressure (SBP) <90 millimeters of mercury (mmHg); 2) supine diastolic blood pressure (DBP) <50 mmHg; 3) supine pulse rate <40 or >120 beats per minute (bpm); 4) change from baseline (increase or decrease) in supine SBP greater than or equal to (>=) 30 mmHg; 5) change from baseline (increase or decrease) in supine DBP >= 20 mmHg.
Time Frame
Baseline through Week 21
Title
Number of Participants With Treatment Emergent ECG Abnormalities
Description
ECG categorical abnormality criteria: 1. PR interval (the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization): a) greater than or equal to (>=) 300 millisecond (msec), b) >=25% increase when baseline is > 200 msec or >=50% increase when baseline is less than or equal to (<=) 200 msec.
2. QRS interval (time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization): a) >=140 msec, b) >=50% increase from baseline.
3. QTcF interval (QT corrected using the Fridericia formula): a) >450 msec and <=480 msec, b) >480 msec and <=500 msec, c) >500 msec, d) >30 msec and <=60 msec increase from baseline, e) >60 msec increase from baseline.
Time Frame
Baseline Through Week 21
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients with T2DM who are treated with metformin and/or diet and exercise
HbA1c greater than or equal to 7% and less than or equal to 10.5%
Total body weight >50 kg (110 lb) with BMI 24.5 to 45.4 kg/m^2
Exclusion Criteria:
Any condition possibly affecting drug absorption
Diagnosis of Type 1 diabetes
History of myocardial infarction, unstable angina, arterial revascularization, stroke, heart failure, or transient ischemic attack within 6 months of screening
Any malignancy not considered cured
Personal or family history of MTC or MEN2, or participants with suspected MTC
Acute pancreatitis or history of chronic pancreatitis
Symptomatic gallbladder disease
Known medical history of active proliferative retinopathy and/or macular edema
Known medical history of active liver disease, including chronic active hepatitis B or C, or primary biliary cirrhosis
Known history of HIV
Supine blood pressure greater than or equal to 160 mmHg (systolic) or greater than or equal to 100 mmHg (diastolic)
Clinically relevant ECG abnormalities
Positive urine drug test
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Pfizer CT.gov Call Center
Organizational Affiliation
Pfizer
Official's Role
Study Director
Facility Information:
Facility Name
Holy Trinity Medical Clinic
City
Harbor City
State/Province
California
ZIP/Postal Code
90710
Country
United States
Facility Name
Innovative Clinical Research, Inc.
City
Harbor City
State/Province
California
ZIP/Postal Code
90710
Country
United States
Facility Name
Long Beach Clinical Trials Services, Inc.
City
Long Beach
State/Province
California
ZIP/Postal Code
90806
Country
United States
Facility Name
National Research Institute
City
Los Angeles
State/Province
California
ZIP/Postal Code
90057
Country
United States
Facility Name
Catalina Research Institute, LLC
City
Montclair
State/Province
California
ZIP/Postal Code
91763
Country
United States
Facility Name
Empire Clinical Research
City
Pomona
State/Province
California
ZIP/Postal Code
91767
Country
United States
Facility Name
Rancho Cucamonga Clinical Research
City
Rancho Cucamonga
State/Province
California
ZIP/Postal Code
91730
Country
United States
Facility Name
Encompass Clinical Research
City
Spring Valley
State/Province
California
ZIP/Postal Code
91978
Country
United States
Facility Name
University Clinical Investigators, Incorporated
City
Tustin
State/Province
California
ZIP/Postal Code
92780
Country
United States
Facility Name
San Fernando Valley Health Institute, LLC
City
Van Nuys
State/Province
California
ZIP/Postal Code
91405
Country
United States
Facility Name
Diablo Clinical Research Incorporated
City
Walnut Creek
State/Province
California
ZIP/Postal Code
94598
Country
United States
Facility Name
Accel Research Sites - DeLand Clinical Research Unit
City
DeLand
State/Province
Florida
ZIP/Postal Code
32720
Country
United States
Facility Name
East Coast Institute for Research, LLC
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32204
Country
United States
Facility Name
East Coast Institute for Research, LLC
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32216
Country
United States
Facility Name
NewPhase Clinical Trials, Corp.
City
Miami Beach
State/Province
Florida
ZIP/Postal Code
33140
Country
United States
Facility Name
New Horizon Research Center
City
Miami
State/Province
Florida
ZIP/Postal Code
33165
Country
United States
Facility Name
Sunshine Research Center, Inc
City
Opa-locka
State/Province
Florida
ZIP/Postal Code
33054
Country
United States
Facility Name
Andres Patron D.O. P.A.
City
Pembroke Pines
State/Province
Florida
ZIP/Postal Code
33026
Country
United States
Facility Name
Ellipsis Group
City
Alpharetta
State/Province
Georgia
ZIP/Postal Code
30022
Country
United States
Facility Name
East Coast Institute for Research, LLC
City
Macon
State/Province
Georgia
ZIP/Postal Code
31210
Country
United States
Facility Name
Cedar Crosse Research Center
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60607
Country
United States
Facility Name
Buynak Clinical Research
City
Valparaiso
State/Province
Indiana
ZIP/Postal Code
46383
Country
United States
Facility Name
Viable Research Management LLC
City
Henderson
State/Province
Nevada
ZIP/Postal Code
89014
Country
United States
Facility Name
Premier Research
City
Trenton
State/Province
New Jersey
ZIP/Postal Code
08611
Country
United States
Facility Name
PharmQuest
City
Greensboro
State/Province
North Carolina
ZIP/Postal Code
27408
Country
United States
Facility Name
Lillestol Research LLC
City
Fargo
State/Province
North Dakota
ZIP/Postal Code
58104
Country
United States
Facility Name
Velocity Clinical Research
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45242
Country
United States
Facility Name
Conrad Clinical Research
City
Edmond
State/Province
Oklahoma
ZIP/Postal Code
73013
Country
United States
Facility Name
Family Medical Associates
City
Levittown
State/Province
Pennsylvania
ZIP/Postal Code
19056
Country
United States
Facility Name
Preferred Primary Care Physicians, Inc.
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15236
Country
United States
Facility Name
Spartanburg Medical Research
City
Spartanburg
State/Province
South Carolina
ZIP/Postal Code
29303
Country
United States
Facility Name
Palmetto Clinical Research
City
Summerville
State/Province
South Carolina
ZIP/Postal Code
29485
Country
United States
Facility Name
Palmetto Primary Care Physicians (physicals only)
City
Summerville
State/Province
South Carolina
ZIP/Postal Code
29485
Country
United States
Facility Name
Dallas Diabetes Research Center
City
Dallas
State/Province
Texas
ZIP/Postal Code
75230
Country
United States
Facility Name
Endocrine Associates
City
Houston
State/Province
Texas
ZIP/Postal Code
77004
Country
United States
Facility Name
PrimeCare Medical Group
City
Houston
State/Province
Texas
ZIP/Postal Code
77024
Country
United States
Facility Name
Juno Research, LLC
City
Houston
State/Province
Texas
ZIP/Postal Code
77074
Country
United States
Facility Name
Northeast Clinical Research of San Antonio
City
Live Oak
State/Province
Texas
ZIP/Postal Code
78233
Country
United States
Facility Name
Sun Research Institute
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78215
Country
United States
Facility Name
DM Clinical Research
City
Tomball
State/Province
Texas
ZIP/Postal Code
77375
Country
United States
Facility Name
Martin Diagnostic Clinic
City
Tomball
State/Province
Texas
ZIP/Postal Code
77375
Country
United States
Facility Name
Rainier Clinical Research Center, Inc.
City
Renton
State/Province
Washington
ZIP/Postal Code
98057
Country
United States
Facility Name
MHAT Dobrich AD
City
Dobrich
ZIP/Postal Code
9300
Country
Bulgaria
Facility Name
Medical Center ASKLEPII OOD
City
Dupnitsa
ZIP/Postal Code
2600
Country
Bulgaria
Facility Name
UMHAT Pulmed
City
Plovdiv
ZIP/Postal Code
4002
Country
Bulgaria
Facility Name
Fourth MHAT - Sofia EAD
City
Sofia
ZIP/Postal Code
1606
Country
Bulgaria
Facility Name
MHAT "Doverie" AD
City
Sofia
ZIP/Postal Code
1632
Country
Bulgaria
Facility Name
MC "New rehabilitation center" EOOD
City
Stara Zagora
ZIP/Postal Code
6000
Country
Bulgaria
Facility Name
GA Research Associates Ltd.
City
Moncton
State/Province
New Brunswick
ZIP/Postal Code
E1G 1A7
Country
Canada
Facility Name
Aggarwal and Associates Limited
City
Brampton
State/Province
Ontario
ZIP/Postal Code
L6T 0G1
Country
Canada
Facility Name
Manna Research (Toronto)
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M9W4L6
Country
Canada
Facility Name
Manna Research (Quebec)
City
Levis
State/Province
Quebec
ZIP/Postal Code
G6W 0M5
Country
Canada
Facility Name
Manna Research (Mirabel)
City
Mirabel
State/Province
Quebec
ZIP/Postal Code
J7J 2K8
Country
Canada
Facility Name
Diex Recherche Sherbrooke Inc.
City
Sherbrooke
State/Province
Quebec
ZIP/Postal Code
J1L 0H8
Country
Canada
Facility Name
Diex Recherche Victoriaville Inc.
City
Victoriaville
State/Province
Quebec
ZIP/Postal Code
G6P 6P6
Country
Canada
Facility Name
Diex Recherche Quebec Inc.
City
Quebec
ZIP/Postal Code
G1N 4V3
Country
Canada
Facility Name
Centre de Recherche Saint-Louis
City
Quebec
ZIP/Postal Code
G1W 4R4
Country
Canada
Facility Name
Alpha Recherche Clinique
City
Quebec
ZIP/Postal Code
G3K2P8
Country
Canada
Facility Name
Belinus Orvosi es Szamitastechnikai Bt
City
Debrecen
ZIP/Postal Code
4025
Country
Hungary
Facility Name
Debreceni Egyetem Klinikai Kozpont
City
Debrecen
ZIP/Postal Code
4032
Country
Hungary
Facility Name
CRU Hungary Kft.
City
Miskolc
ZIP/Postal Code
3529
Country
Hungary
Facility Name
Borbanya Praxis Egeszsegugyi KFT
City
Nyiregyhaza
ZIP/Postal Code
H-4405
Country
Hungary
Facility Name
Clinfan Kft.
City
Szekszard
ZIP/Postal Code
H-7100
Country
Hungary
Facility Name
Yonsei University-Wonju Severance Christian Hospital
City
Wonju-si
State/Province
Gangwon-do
ZIP/Postal Code
26426
Country
Korea, Republic of
Facility Name
Hanyang University Guri Hospital
City
Guri-si
State/Province
Gyeonggi-do
ZIP/Postal Code
11923
Country
Korea, Republic of
Facility Name
Ajou University Hospital
City
Suwon-si
State/Province
Gyeonggi-do
ZIP/Postal Code
16499
Country
Korea, Republic of
Facility Name
Samsung Medical Center
City
Gangnam-Gu
State/Province
Seoul
ZIP/Postal Code
06351
Country
Korea, Republic of
Facility Name
Zdrowie Osteo-Medic s.c. Lidia i Artur Racewicz, Agnieszka i Jerzy Supronik
City
Bialystok
ZIP/Postal Code
15-351
Country
Poland
Facility Name
Medyczne Centrum Diabetologiczno-Endokrynologiczno-Metaboliczne DIAB-ENDO-MET Sp. z o. o.
City
Krakow
ZIP/Postal Code
31-261
Country
Poland
Facility Name
Prywatny Gabinet Lekarski i Wizyty Lekarskie Jan Ruxer
City
Lodz
ZIP/Postal Code
94-060
Country
Poland
Facility Name
MEDICOME Sp. z o.o.
City
Oswiecim
ZIP/Postal Code
32-600
Country
Poland
Facility Name
KO-MED CENTRA KLINICZNE Sp. z o.o. Ośrodek Badań Klinicznych w Puławach
City
Puławy
ZIP/Postal Code
24-100
Country
Poland
Facility Name
Centralny Szpital Kliniczny MSWiA
City
Warszawa
ZIP/Postal Code
02-507
Country
Poland
Facility Name
Metabol KLINIK s.r.o.
City
Bratislava
ZIP/Postal Code
811 08
Country
Slovakia
Facility Name
Medispektrum, s.r.o
City
Bratislava
ZIP/Postal Code
851 01
Country
Slovakia
Facility Name
HUMAN-CARE, s.r.o.
City
Kosice
ZIP/Postal Code
040 01
Country
Slovakia
Facility Name
SchronerMED s.r.o.
City
Moldava nad Bodvou
ZIP/Postal Code
04501
Country
Slovakia
Facility Name
Funkystuff, s.r.o.
City
Nove Zamky
ZIP/Postal Code
940 01
Country
Slovakia
Facility Name
DIAB s.r.o.
City
Roznava
ZIP/Postal Code
048 01
Country
Slovakia
Facility Name
MUDr. Jana Rociakova, s.r.o.
City
Zilina
ZIP/Postal Code
010 01
Country
Slovakia
Facility Name
Far Eastern Memorial Hospital
City
New Taipei City
ZIP/Postal Code
220
Country
Taiwan
Facility Name
Taichung Veterans General Hospital
City
Taichung
ZIP/Postal Code
40705
Country
Taiwan
Facility Name
National Cheng Kung University Hospital
City
Tainan
ZIP/Postal Code
704
Country
Taiwan
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
IPD Sharing URL
https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests
Links:
URL
https://pmiform.com/clinical-trial-info-request?StudyID=C3421005
Description
To obtain contact information for a study center near you, click here.
Learn more about this trial
A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus
We'll reach out to this number within 24 hrs